Novo Nordisk’s Wegovy In Medicare Part D: Coverage May Not Be The Only Problem
Executive Summary
Prospect of facing price negotiation in Part D may lead Novo Nordisk to consider earlier-than-currently-planned generic competition for its older semaglutide drug for diabetes, Ozempic.
You may also be interested in...
Wegovy’s Cardiovascular Benefits May Improve, But Not Transform, Insurance Coverage In Obesity
Novo Nordisk’s obesity drug lowered adverse cardiovascular events by an impressive 20% in a pivotal study. However, payers may still want data on how paying for obesity drugs could lower their overall medical expenses.
FDA’s Califf Defends CMS Drug Coverage Role, Blames Rx Industry Prices For US Health Woes
US FDA Commissioner defends role of his sister-agency CMS in determining drug coverage after his agency’s approvals. Califf weighs in on a variety of drug pricing topics – including the IRA, accelerated approval pricing, and obesity drug coverage – at the annual BIO meeting in Boston.
FDA’s Califf Defends CMS Drug Coverage Role, Blames Rx Industry Prices For US Health Woes
US FDA Commissioner defends role of his sister-agency CMS in determining drug coverage after his agency’s approvals. Califf weighs in on a variety of drug pricing topics – including the IRA, accelerated approval pricing, and obesity drug coverage – at the annual BIO meeting in Boston.